专题：2025中国企业竞争力年会 专题：2025中国企业竞争力年会 "2025中国企业竞争力年会"于12月9日至10日在北京举行，浙江寿仙谷医药股份有限公司董事会秘书刘 国芳在演讲中介绍，她是寿仙谷灵芝孢子粉的忠实粉丝，是从39岁开始服用灵芝孢子粉的，服用11年 了，今年50岁了，给她三个感受： 第一个是睡眠特别好，一沾枕头就睡； 第二个是11年没有吃过一粒感冒药，包括阳了也没有吃过药，就是每一天精力旺盛，白天精神好，晚上 睡得好； 第三个是她11年也没跨入过美容院，但皮肤老化的速度相对来说还是比较慢的。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李思阳 "2025中国企业竞争力年会"于12月9日至10日在北京举行，浙江寿仙谷医药股份有限公司董事会秘书刘 国芳在演讲中介绍，她是寿仙谷灵芝孢子粉的忠实粉丝，是从39岁开始服用灵芝孢子粉的，服用11年 了，今年50岁了，给她三个感受： 第一个是睡眠特别好，一沾枕头就睡； 第二个是11年没有吃过一粒感冒药，包括阳了也没有吃过药，就是每一天精力旺盛，白天精神好，晚上 睡 ...

0:00 浙江寿仙谷医药股份有限公司董事会秘书刘国芳：中国正处于高质量发展的时期，人们对高水平健康的 追求趋势不会变。中国进入了银发经济时代，60岁以上的人口占比达到了30%，人们对中药的功效越来 越接受和认可。所以，未来大健康产业会是一个发展潜力巨大的产业，也会是一个复苏比较快的行业。 ...

证券代码：603896 证券简称：寿仙谷 公告编号：2025-077 债券代码：113660 债券简称：寿22转债 浙江寿仙谷医药股份有限公司 关于举办2025年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药股份有限公司（以下简 称"公司"或"寿仙谷"）情况，公司拟举办2025年第二次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025年12月23日8:50-17:00 2、接待地点：公司基地一寿仙谷有机国药养生园；公司总部一浙江省武义县黄龙三路12号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李振宇、董事兼副总经理林荣 志、董事兼副总经理徐靖、董事黄俊华、副总经理兼董事会秘书刘国芳、财务负责人祝彪、副总经理王 汉波、投资者服务部总监曹秀娟（如遇特殊情况，参会人员会有所调整） 4、活动日程： ■ 注：①投资者可根据自己的行程选择合适的集合地点，公司将统一安排车辆前往基地参观；自驾的投资 者可以将 ...

证券日报网讯 12月9日，寿仙谷在互动平台回答投资者提问时表示，公司已开始布局国际市场，特别是 在中医药文化认同度较高的东南亚地区。 （文章来源：证券日报） ...

浙江寿仙谷医药股份有限公司 关于举办 2025 年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-077 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药 股份有限公司（以下简称"公司"或"寿仙谷"）情况，公司拟举办 2025 年第二 次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025 年 12 月 23 日 8:50-17:00 2、接待地点：公司基地—寿仙谷有机国药养生园；公司总部—浙江省武义 县黄龙三路 12 号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李 振宇、董事兼副总经理林荣志、董事兼副总经理徐靖、董事黄俊华、副总经理兼 董事会秘书刘国芳、财务负责人祝彪、副总经理王汉波、投资者服务部总监曹秀 娟（如遇特殊情况，参会人员会有所调 ...

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2025 年第二次临时股东会 会议资料 $$=0\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi$$ 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 目 录 | 2025 | 年第二次临时股东会会议议程 2 | | --- | --- | | 2025 | 年第二次临时股东会会议须知 4 | | | 议案一：关于变更公司注册资本、取消监事会暨修订《公司章程》的议案 6 | | | 议案二：关于修订部分公司治理制度的议案 14 | 1 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议议程 一、会议召集人：浙江寿仙谷医药股份有限公司董事会 二、会议召开的日期、时间： 现场会议时间：2025 年 12 月 23 日 14:00 网络投票起止时间：自 ...

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on December 23, 2025 [2][5] - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [3][6] - The company aims to enhance participation from small and medium investors by providing reminder services for the meeting [3][4] Group 2 - The company plans to provide a guarantee of 600 million RMB for its wholly-owned subsidiaries within a comprehensive credit limit for 2026 [20][21] - As of the announcement date, the actual guarantee balance provided to subsidiaries is 190 million RMB [21][26] - The company intends to apply for a total credit limit of up to 800 million RMB from various financial institutions [21][25] Group 3 - The company has decided to postpone the expected usable status date for two fundraising investment projects from November 30, 2025, to June 30, 2026 [29][36] - The postponement does not alter the total investment amount or construction scale of the projects [29][37] - The company emphasizes that the delay is a cautious decision based on market conditions and will not significantly impact its normal operations [37][39] Group 4 - The company has revised its remuneration management system for directors and senior management to align with current regulations and improve internal governance [42] - The revised system was approved during the sixth meeting of the fifth board of directors [42][41] Group 5 - The company plans to use up to 250 million RMB of temporarily idle fundraising and up to 1 billion RMB of idle self-owned funds for cash management in 2026 [55][56] - The investment will focus on low-risk financial products such as structured deposits and large certificates of deposit [58][64] - The decision to manage idle funds aims to enhance capital efficiency without affecting ongoing projects or normal operations [70][71]

证券日报网讯11月28日晚间，寿仙谷（603896）发布公告称，公司对外担保不存在逾期情形。 ...